Top Ten Common Prejudices About Polyethylene Naphthalate Market.
"Global Transthyretin Amyloidosis Treatment Market, By Drug (Inostersen, Partisiran, Tafamidis, and Others), By Indication (Wild Type ATTR Amyloidosis, and Hereditary ATTR Amyloidosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa) - Trends, Analysis, and Forecasts"
An increase in the prevalence of disease, a rise in the population of African origin, increased awareness, improved diagnostic procedures, improved health care services, rapid economic growth in developing countries, and increased research and development activity are likely to drive the global transthyretin amyloidosis treatment market. According to the Amyloidosis Foundation, ATTR has about 126 different genetic variations, while non-transthyretin hereditary amyloidosis illnesses have up to 53 different genetic variations.
According to published reports on transthyretin amyloidosis, the global prevalence of TTR-FAP is estimated to be around 10,000 people, or 1.1 per 100,000 people. Patients with the disease are often between the ages of 30 and 40 years old. TTR-CM has also been shown to impact older guys, particularly those aged 65 and up. TTR-FAP causes 100 different types of mutations in the transthyretin gene, which causes protein misfolding. From an affected parent, there is only a 50% probability of passing the mutation on to the following generation. The mutation that causes familial amyloid cardiomyopathy, on the other hand, is commonly found.
The global ATTR market is expected to grow rapidly over the forecast period, owing to the likelihood of more ATTR therapeutic drugs being launched, an increase in the African-American population due to their genetic susceptibility to amyloidosis, increased healthcare awareness, and rising average income. Stringent regulatory restrictions, the high cost of ATTR medications, inaccurate diagnosis of ATTR illnesses, and clinical trial limits might all slow the market's growth. The lack of awareness of this ailment and the lack of effective diagnostic tools in middle-income nations are the market's biggest obstacles.
The “Global Transthyretin Amyloidosis Treatment Market” includes 60 market data tables* and 35 figures*, as well as 140 slides and an in-depth TOC. Drug (Inostersen, Partisiran, Tafamidis, and Others), Indication (Wild Type ATTR Amyloidosis and Hereditary ATTR Amyloidosis), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Up to 2029, trends, analysis, and forecast
Comments
Post a Comment